<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106130</url>
  </required_header>
  <id_info>
    <org_study_id>ID_MotiReb_1201</org_study_id>
    <nct_id>NCT02106130</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of Mosapride and Rebamipide</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Mosapride Citrate and Rebamipide After Oral Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators investigate the potential pharmacokinetic drug-drug interaction between
      Mosapride citrate 5 mg and Rebamipide 100 mg in healthy male volunteers who receive Mosapride
      citrate 5 mg, Rebamipide 100 mg, and both together in a 2 period repeatedly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, drug-tolerance, pharmacokinetics of Mosapride citrate 5 mg or
      Rebamipide 100 mg monotherapy or Mosapride citrate 5 mg and Rebamipide 100 mg combination in
      healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss of Mosapirde citrate 5mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Mosapirde citrate 5mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss of Rebamipide 100mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss of Rebamipide 100mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast,ss of Mosapride citrate 5mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,ss of Mosapride citrate 5mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Mosapride citrate 5mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Mosapride citrate 5mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of Mosapride citrate 5mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast,ss of Rebamipide 100mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf,ss of Rebamipide 100mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of Rebamipide 100mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Rebamipide 100mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of Rebamipide 100mg</measure>
    <time_frame>D-1 D2, D7, D9: pre-dose / D3~4, D10~11: pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 25 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>R - R+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R+M - R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M - R+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R+M - M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide</intervention_name>
    <description>oral administration, 3 times/day</description>
    <arm_group_label>R - R+M</arm_group_label>
    <arm_group_label>R+M - R</arm_group_label>
    <arm_group_label>M - R+M</arm_group_label>
    <arm_group_label>R+M - M</arm_group_label>
    <other_name>Mucosta® Tab.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosapride citrate</intervention_name>
    <description>oral administration, 3 times/day</description>
    <arm_group_label>R - R+M</arm_group_label>
    <arm_group_label>R+M - R</arm_group_label>
    <arm_group_label>M - R+M</arm_group_label>
    <arm_group_label>R+M - M</arm_group_label>
    <other_name>Gasmotin® tab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers, age 20 to 45 years

          2. Body weight ≥ 55kg (male), ≥ 50kg (female)

          3. Body weight index (BMI) 18.5 ~ 25

          4. Acceptable serum test, hematologic test, blood chemistry examination, urin test and
             ECG, physical examination during screening

          5. Subject decided to participate voluntarily and gave written Informed consent to comply
             with the instructions after listening to and fully understanding the detailed
             explanation about this trial.

        Exclusion Criteria:

          1. Subject has clinically significant liver, kidney, neurologic, immunologic,
             respiratory, endocrine disease or hematologic·oncologic disease, cardiovascular
             disease or psychiatric disease (mood disorder, compulsive disorder etc.) or such
             medical history (including subject with hepatitis virus in case of liver disease).

          2. Subject has history of gastrointestinal disease (such as Crohn's disease, ulcer, acute
             or chronic pancreatitis etc.) or gastrointestinal surgery (except simple appendectomy
             or hernia operation) that can affect the absorption of the study drug.

          3. Subject has hypersensitivity reaction to drug (aspirin, antibiotics, including study
             durgs, etc.) or history of clinically significant hypersensitivity reaction.

          4. Systolic blood pressure &gt; 150mmHg or &lt;90mmHg, Diastolic blood pressure &gt;100mmHg or
             &lt;50mmHg(Sitting blood pressure) during the screening procedure

          5. Subject has history of drug abuse or tested positive to abused drug in the urine drug
             screening test.

          6. For women, pregnant or breastfeeding woman or woman who was confirmed to be pregnant
             in the pregnancy test

          7. Subject takes caffeine-containing food 5 cups per day

          8. Subject continually drinks (in excess of 210g/week)

          9. Subject smokes 10 cigarettes or more in one day

         10. Subject took any prescribed drug or oriental medicine within 2 weeks prior to the
             first medication or any over-the-counter (OTC) drug within 1 week prior to the first
             medication (however, the subject can be included if other criteria are met according
             to the discretion of the investigator).

         11. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products
             within 30 days prior to the first dosing

         12. Subject participated in another study and received medication within 2 months prior to
             the first medication day.

         13. Subject received whole blood transfusion (500 mL) within 2 months prior to the first
             medication or blood transfusion within 1 month prior to the first medication.

         14. Subject was judged not to be eligible according to the discretion of the investigator
             for other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-ok Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Health System, Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mosapride citrate</keyword>
  <keyword>Rebamipide</keyword>
  <keyword>pharmacokinetic drug drug interaction</keyword>
  <keyword>oral administration</keyword>
  <keyword>healthy male subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Mosapride</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

